Evidence map›Paper›PMID 33762312›Full record

ArticleBMJ open diabetes research & care2021

Skin autofluorescence predicts cancer in subjects with type 2 diabetes.

Ninon Foussard, Alice Larroumet, Marine Rigo, Kamel Mohammedi, Laurence Baillet-Blanco, Pauline Poupon, Marie Monlun, Maxime Lecocq, Anne-Claire Devouge, Claire Ducos and 3 more

Open access · goldAbstract read
In one paragraph

Article in BMJ open diabetes research & care, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
5.9field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 45 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Ninon FoussardNutrition-Diabetology, CHU de Bordeaux, Hôpital Haut-Lévêque, Pessac, France ninonfoussard@yahoo.fr.ORCID 0000-0003-1317-5662
Alice LarroumetNutrition-Diabetology, CHU de Bordeaux, Hôpital Haut-Lévêque, Pessac, France.ORCID 0000-0002-0416-9175
Marine RigoNutrition-Diabetology, CHU de Bordeaux, Hôpital Haut-Lévêque, Pessac, France.
Kamel MohammediNutrition-Diabetology, CHU de Bordeaux, Hôpital Haut-Lévêque, Pessac, France.
Laurence Baillet-BlancoNutrition-Diabetology, CHU de Bordeaux, Hôpital Haut-Lévêque, Pessac, France.
Pauline PouponNutrition-Diabetology, CHU de Bordeaux, Hôpital Haut-Lévêque, Pessac, France.
Marie MonlunNutrition-Diabetology, CHU de Bordeaux, Hôpital Haut-Lévêque, Pessac, France.ORCID 0000-0002-2376-2935
Maxime LecocqNutrition-Diabetology, CHU de Bordeaux, Hôpital Haut-Lévêque, Pessac, France.
Anne-Claire DevougeNutrition-Diabetology, CHU de Bordeaux, Hôpital Haut-Lévêque, Pessac, France.ORCID 0000-0003-2335-4648
Claire DucosNutrition-Diabetology, CHU de Bordeaux, Hôpital Haut-Lévêque, Pessac, France.
Marion LiebartNutrition-Diabetology, CHU de Bordeaux, Hôpital Haut-Lévêque, Pessac, France.
Quentin BattagliniNutrition-Diabetology, CHU de Bordeaux, Hôpital Haut-Lévêque, Pessac, France.
Vincent RigalleauNutrition-Diabetology, CHU de Bordeaux, Hôpital Haut-Lévêque, Pessac, France.
Centre Hospitalier Universitaire de Bordeaux · FRInserm · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionSubjects with type 2 diabetes have an excess risk of cancer. The potential role of advanced glycation end products (AGEs) accumulated during long-term hyperglycemia in cancer development has been suggested by biological studies but clinical data are missing. AGEs can be estimated by measuring the skin autofluorescence. We searched whether the skin autofluorescence could predict new cancers in persons with type 2 diabetes. RESEARCH DESIGN AND

methodsFrom 2009 to 2015, we measured the skin autofluorescence of 413 subjects hospitalized for uncontrolled or complicated type 2 diabetes, without any history of cancer. The participants were followed for at least 1 year and the occurrences of new cancers were compared according to their initial skin autofluorescences.

resultsThe participants were mainly men (57.9%), with poorly controlled (HbA1c 72±14 mmol/mol or 8.7%±1.8%) and/or complicated type 2 diabetes. Their median skin autofluorescence was 2.6 (2.2-3.0) arbitrary units. Forty-five new cancer cases (10.9%) were registered during 4.8±2.3 years of follow-up: 75.6% of these subjects had skin autofluorescence higher than the median (χ

conclusionsSkin autofluorescence, a potential marker of glycemic memory, predicts the occurrence of cancer in subjects with type 2 diabetes. This relation provides a new clinical argument for the role of AGEs in cancer. Their estimation by measuring the skin autofluorescence may help select subjects with diabetes in cancer screening programs.

Indexed as

Diabetes Mellitus, Type 2NeoplasmsBlood GlucoseGlycation End Products, AdvancedHumansMaleSkinBlood GlucoseGlycation End Products, Advancedadvanced glycation end productbiomarkerscancertype 2 diabetes

Identifiers

PMID33762312
PMCPMC7993362
OpenAlexW3138251191

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.